Share of the pharma major fell about 4 per cent in the first one hour of the trade on Friday. Experts see concerns over the US business, as well as, pressure on operating performance as key drags. Despite near-term headwinds, most brokerage firms maintained their rating and target prices but slashed earnings per share (EPS) estimates for FY23-24.
Groww’s Ishan Bansal sees structural shift in derivatives participation post regulatory changes
Derivatives business faces a structural reset post FY25 regulatory changes, with growth now driven by a smaller but stable customer base, increased market volatility, and
April 21, 2026